Quantcast

Latest antibodies Stories

2014-03-26 23:24:54

Dr. Pierre-Allain Girod to Present on Data on Engineering CHO Cell Lines for Enhanced Production of Monoclonal Antibodies and Fc:Fusion Proteins Geneva, Switzerland (PRWEB) March 26, 2014 Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the Company’s chief scientific officer, Pierre-Allain Girod, Ph.D., will present, “Selexis SURE CHO-Mplus™...

2014-03-24 08:28:11

MONROVIA, Calif., March 24, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat, Ph.D., Chief Executive Officer, will present at the 21st Annual BioCentury Future Leaders in the Biotech Industry Conference on Friday, March 28, 2014 at 9:30 a.m. EDT at the Millennium Broadway Hotel...

2014-03-18 08:32:26

Telephus Advances TPH 101 Program Towards Candidate Selection SAN DIEGO, March 18, 2014 /PRNewswire/ -- BioAtla, a global biotechnology company focused on the development of differentiated biological therapeutics, and Telephus Medical LLC, a leader in the development of vaccine products to prevent periprosthetic joint infections and accompanying osteomyelitis in orthopedic procedures, today announced that BioAtla has successfully completed a key protein engineering phase of Telephus'...

2014-03-16 16:20:46

CAMBRIDGE, England, March 16, 2014 /PRNewswire/ -- Kymab, a monoclonal antibody biopharmaceutical company founded on research from the Wellcome Trust Sanger Institute, announced today the publication in Nature Biotechnology of a paper describing its breakthrough therapeutic antibody discovery technology, Kymouse(TM) (http://dx.doi.org). Scientists at Kymab have engineered a mouse with the full set of genes encoding the human antibody repertoire, calling this...

2014-03-13 16:27:58

DUBLIN, March 13, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/43nvqj/cancer_monoclonal) has announced the addition of the "Cancer Monoclonal Antibodies Market Forecast to 2017" [http://www.researchandmarkets.com/research/43nvqj/cancer_monoclonal ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Cancer, one of the leading causes of death worldwide, affected approximately 13 Million...

2014-03-13 08:28:48

MONROVIA, Calif., March 13, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release fourth quarter and full year 2013 financial results after market close on Wednesday, March 19, 2014. Xencor management will host a webcast and conference call the same day at 4:30 p.m. EDT (1:30 p.m. PDT) to...

2014-03-13 08:28:19

SAN DIEGO, March 13, 2014 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced a strategic immuno-oncology collaboration with TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company. Under the terms of the agreement, AnaptysBio has granted TESARO exclusive rights to antibody programs targeting PD-1, TIM-3 and LAG-3, including monospecific and dual reactive antibody drug candidates. Antibody...

2014-03-11 16:25:50

AUSTIN, Texas, March 11, 2014 /PRNewswire/ -- XBiotech announced today that the United States Patent and Trademark Office (USPTO) granted another key patent to support the Company's growing portfolio around its lead product candidate. The new patent grants XBiotech exclusive rights to target a unique molecule associated with chronic sterile inflammation. The patent relates to antibodies and methods of using these antibodies to treat, prevent, and detect disease progression associated...

2014-03-07 08:21:14

DUBLIN, Mar. 07, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/cl5vpz/antibody_target ) has announced the addition of the "Concise Database for Antibody Target, Technology & Pipeline: 1-Year Subscription" subscription to their offering. (Logo:http://photos.prnewswire.com/prnh/20130307/600769) Subscription to La Merie Publishing's proprietary Antibody Database provides online access to information about more than 2,400 project entries for...

2014-03-05 08:29:20

DUBLIN, March 5, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/r8hfhg/fc_protein_and) has announced the addition of the "Fc Protein and Glycoengineered Antibodies Market" [http://www.researchandmarkets.com/research/r8hfhg/fc_protein_and ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Engineered antibodies are antibody based therapeutics, which are gaining increasing attention from...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related